111 results
Page 2 of 6
8-K
EX-99.1
zlqabhimwiuhh
19 Jun 20
Rexahn and Ocuphire Enter into Definitive Merger Agreement
9:02am
425
EX-99.1
n23ay2kjniqbkg29j
19 Jun 20
Business combination disclosure
9:00am
425
h0j16z8z54u196ghih5i
18 Jun 20
Business combination disclosure
9:14am
8-K
EX-99.1
0t34ldurth7k4tle
7 Aug 19
Rexahn Pharmaceuticals Reports Second Quarter 2019 Financial Results and Provides Update on RX-3117 Development
6:43am
8-K
EX-99.1
0e5ksg77qsm92 vt
29 May 19
Rexahn Announces Move to Nasdaq
12:56pm
8-K
EX-99.1
z02nd
16 Apr 19
Rexahn and BioSense Global Announce Collaboration and License Agreement for RX-3117 in Greater China
8:03am
8-K
EX-99.1
zcfrmso 2k
12 Apr 19
Amendments to Articles of Incorporation or Bylaws
8:15am
8-K
EX-99.1
klh6wk i5zhomjx
1 Mar 19
Rexahn Pharmaceuticals Appoints Lara S. Sullivan to its Board of Directors
5:10pm
424B5
ppte6xl1oitfyi2nl70z
24 Jan 19
Prospectus supplement for primary offering
5:15pm
8-K
EX-99.1
2hq whna9xn
22 Jan 19
Rexahn Presents Updated Preliminary Data on RX-3117 in Pancreatic Cancer
4:48pm
424B5
1owosxyx
22 Jan 19
Prospectus supplement for primary offering
4:47pm
8-K
EX-99.1
ozkypesetn2p1tjyz
3 Dec 18
Rexahn Pharmaceuticals Appoints Gil Price to its Board of Directors
4:53pm
8-K
EX-99.1
q58g4b aodqo54q
16 Nov 18
Rexahn Pharmaceuticals Announces Leadership Transition
4:45pm